uniQure (NASDAQ:QURE) Shares Gap Up Following Analyst Upgrade

uniQure (NASDAQ:QUREGet Rating)’s stock price gapped up before the market opened on Wednesday after The Goldman Sachs Group raised their price target on the stock from $47.00 to $57.00. The stock had previously closed at $23.00, but opened at $23.79. The Goldman Sachs Group currently has a buy rating on the stock. uniQure shares last traded at $24.25, with a volume of 9,095 shares changing hands.

QURE has been the topic of a number of other research reports. Cantor Fitzgerald restated an “overweight” rating on shares of uniQure in a research report on Thursday, November 3rd. StockNews.com began coverage on shares of uniQure in a research report on Wednesday, October 12th. They set a “sell” rating on the stock. Wells Fargo & Company lowered their price objective on shares of uniQure from $34.00 to $24.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 9th. Chardan Capital lowered their price objective on shares of uniQure from $65.00 to $60.00 and set a “buy” rating on the stock in a research report on Tuesday, August 9th. Finally, TheStreet downgraded shares of uniQure from a “c-” rating to a “d” rating in a research report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and an average price target of $48.71.

Insiders Place Their Bets

In other uniQure news, VP Alexander Edward Kuta III sold 2,306 shares of the stock in a transaction that occurred on Wednesday, September 21st. The shares were sold at an average price of $18.65, for a total value of $43,006.90. Following the transaction, the vice president now directly owns 92,890 shares in the company, valued at $1,732,398.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.10% of the company’s stock.

Institutional Trading of uniQure

Institutional investors and hedge funds have recently modified their holdings of the company. Meeder Asset Management Inc. bought a new stake in shares of uniQure during the 1st quarter valued at $27,000. Captrust Financial Advisors raised its position in shares of uniQure by 1,392.3% during the 2nd quarter. Captrust Financial Advisors now owns 1,940 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 1,810 shares during the period. US Bancorp DE raised its position in shares of uniQure by 108.2% during the 2nd quarter. US Bancorp DE now owns 1,978 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,028 shares during the period. PNC Financial Services Group Inc. raised its position in shares of uniQure by 152.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,038 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,231 shares during the period. Finally, Covestor Ltd bought a new stake in shares of uniQure during the 1st quarter valued at $50,000. 86.46% of the stock is currently owned by institutional investors.

uniQure Stock Up 14.6 %

The stock has a market capitalization of $1.23 billion, a P/E ratio of -9.80 and a beta of 0.96. The company’s 50-day moving average price is $19.73 and its 200 day moving average price is $19.13. The company has a debt-to-equity ratio of 0.24, a quick ratio of 7.20 and a current ratio of 7.26.

About uniQure

(Get Rating)

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.

Read More

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.